Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Teladoc Health, Inc. (TDOC)

Teladoc Health Q3 revenue falls 3% to $605.1 million; net loss narrows

Mixed Impact 3 of 5 earnings Written later

Teladoc Health reported third quarter 2026 revenue of $605.1 million, down 3% from a year earlier, while its net loss narrowed to $26.9 million, or $0.15 per share, from $49.5 million, or $0.28 per share. The company also issued full-year and fourth-quarter 2026 outlook ranges, which show revenue of $2,395 million to $2,441 million for the year and a net loss per share of ($0.95) to ($0.75).

Key points

  • Q3 2026 revenue was $605.1 million, down 3%; BetterHelp revenue fell 13% to $206.6 million while Integrated Care rose 2% to $398.5 million.
  • Q3 2026 adjusted EBITDA was $79.4 million, up 14% from $69.9 million in Q3 2025.
  • Q3 2026 net loss included $88.3 million of intangible amortization and $4.4 million of restructuring costs.
  • Full-year 2026 outlook: revenue $2,395 million to $2,441 million; adjusted EBITDA $277 million to $303 million; Q4 2026 revenue $569 million to $615 million.

The filing

CompanyTeladoc Health, Inc. (TDOC)
Form8-K, current report
Filed with the SECOct 28, 2026, 4:04 PM ET
Accession number0001477449-26-000050

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.